• Media type: E-Article
  • Title: Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
  • Contributor: Zirngibl, Felix; Flemmig, Carina; Lang, Peter; Künkele, Annette; Eggert, Angelika; Schulte, Johannes H.; Deubzer, Hedwig E.
  • Published: MDPI AG, 2020
  • Published in: Children, 7 (2020) 11, Seite 198
  • Language: English
  • DOI: 10.3390/children7110198
  • ISSN: 2227-9067
  • Origination:
  • Footnote:
  • Description: Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic acid (TA), used to prevent/treat excessive blood loss, are rare. We present the clinical course of two young patients (22 and 56 months) receiving busulfan/melphalan (Bu/Mel) high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) to treat high-risk neuroblastoma, who developed hepatic sinusoidal obstruction syndrome (SOS) within 48 h after systemic TA treatment for a hemodynamically relevant hemorrhage. Defibrotide treatment resolved hepatic SOS, but the short time between TA administration and SOS onset suggests a causal association.
  • Access State: Open Access